The present research was aimed towards developing an oral dosage form having Lisinopril sustained release. Lisinopril is the BCS Class III drug under the Biopharmaceutics Classification System. There are various polymers used in trial-and-error method, among these HPMC and Eudragit and were taken in the ratio 2:5, had successfully retarded the release of Lisinopril for 24hrs in a rate-controlled manner. Hence the present work suggests HPMC as suitable rate retarding polymer for control release formulation of Lisinopril and the study recommends in vivo evaluation of the best optimized formula. As per the proto type evaluation results it was concluded that wet granulation is the best possible method of granulation for the present work. Pre-formulation studies were conducted to check the drug polymer and excipients compatibility and the results had confirmed compatibility among them. Granules were evaluated for tests like bulk density, tap density, compressibility index before compression.